Legend Biotech Corp - רווח נקי למניה ב-12 החודשים האחרונים LEGN

The effective alliance with J&J regarding CARVYKTI confirms the managerial success of Legend Biotech (LEGN). The 12-month YoY change in net income per share reflects this trend, where the parameter value equals 99.00. Stability is maintained by a staff of top biologists attracted by stock options, while the high cost of therapy, covered by insurance, guarantees the company exceptional pricing power.

An investment audit of Legend Biotech (LEGN) requires an analysis of profit dynamics, where the annual growth of basic net income per share (TTM) measures the percentage change in EPS over a rolling year relative to the previous period. This metric reflects the scaling efficiency of automated gene therapy production, allowing this chart to assess the extent to which the technological sterility of bioreactors converts into real growth in shareholder value.